Want to join the conversation?
$OREX 2Q15 Call: In partnership with Takeda, resolved all outstanding disputes between the companies. Reached agreement and finalized and amended a restated collaboration agreement. In terms of US performance, Contrave has quickly established itself as the most prescribed branded weight loss medication.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.